{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:37:50Z","timestamp":1790829470072,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["IZSEZ0_193593"],"award-info":[{"award-number":["IZSEZ0_193593"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We envisage the development of new Brain Health Services to achieve primary and secondary dementia prevention. These services will complement existing memory clinics by targeting cognitively unimpaired individuals, where the focus is on risk profiling and personalized risk reduction interventions rather than diagnosing and treating late-stage disease. In this article, we review key potentially modifiable risk factors and genetic risk factors and discuss assessment of risk factors as well as additional fluid and imaging biomarkers that may enhance risk profiling. We then outline multidomain measures and risk profiling and provide practical guidelines for Brain Health Services, with consideration of outstanding uncertainties and challenges. Users of Brain Health Services should undergo risk profiling tailored to their age, level of risk, and availability of local resources. Initial risk assessment should incorporate a multidomain risk profiling measure. For users aged 39\u201364, we recommend the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Dementia Risk Score, whereas for users aged 65 and older, we recommend the Brief Dementia Screening Indicator (BDSI) and the Australian National University Alzheimer\u2019s Disease Risk Index (ANU-ADRI). The initial assessment should also include potentially modifiable risk factors including sociodemographic, lifestyle, and health factors. If resources allow, <jats:italic>apolipoprotein E \u025b4<\/jats:italic> status testing and structural magnetic resonance imaging should be conducted. If this initial assessment indicates a low dementia risk, then low intensity interventions can be implemented. If the user has a high dementia risk, additional investigations should be considered if local resources allow. Common variant polygenic risk of late-onset AD can be tested in middle-aged or older adults. Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative. Advanced imaging with 18-fluorodeoxyglucose positron emission tomography (FDG-PET) or amyloid PET may be informative in high risk users to clarify the nature and burden of their underlying pathologies. Cerebrospinal fluid biomarkers are not recommended for this setting, and blood-based biomarkers need further validation before clinical use. As new technologies become available, advances in artificial intelligence are likely to improve our ability to combine diverse data to further enhance risk profiling. Ultimately, Brain Health Services have the potential to reduce the future burden of dementia through risk profiling, risk communication, personalized risk reduction, and cognitive enhancement interventions.<\/jats:p>","DOI":"10.1186\/s13195-021-00895-4","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T18:06:19Z","timestamp":1633975579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services\u2014part 2 of 6"],"prefix":"10.1186","volume":"13","author":[{"given":"Janice M.","family":"Ranson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Rittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabina","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Brayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blossom C. M.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-8993","authenticated-orcid":false,"given":"Daniele","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Task Force for Brain Health Services","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Abramowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Berthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Bieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Brayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Brioschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Ch\u00e9telat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Demonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dodich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Kivipelto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"J. Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McWhirter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Miniussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"issue":"10","key":"895_CR1","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/alz.12132","volume":"16","author":"GB Frisoni","year":"2020","unstructured":"Frisoni GB, Molinuevo JL, Altomare D, Carrera E, Barkhof F, Berkhof J, et al. Precision prevention of Alzheimer\u2019s and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimers Dement. 2020;16(10):1457\u201368. https:\/\/doi.org\/10.1002\/alz.12132.","journal-title":"Alzheimers Dement"},{"key":"895_CR2","doi-asserted-by":"publisher","unstructured":"Altomare D, Molinuevo JL, Ritchie C, Ribaldi F, Carrera E, Dubois B, Jessen F, McWhirter L, Scheltens P, van der Flier WM, Vellas B, D\u00e9monet JF, Frisoni GB. Brain Health Services: Organization, structure and challenges for implementation. A user manual for\u00a0Brain Health Services \u2013 Part 1 of 6.\u00a0Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00827-2.","DOI":"10.1186\/s13195-021-00827-2"},{"key":"895_CR3","doi-asserted-by":"publisher","unstructured":"Visser LNC, Minguillon C, S\u00e1nchez-Benavides G, Abramowicz M, Altomare D, Fauria K, Frisoni GB, Georges J, Ribaldi F, Scheltens P, van der Schaar J, Zwan M, van der Flier WM, Molinuevo JL. Dementia risk communication. A user manual for Brain Health Services \u2013 Part 3 of 6.\u00a0Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00840-5.","DOI":"10.1186\/s13195-021-00840-5"},{"key":"895_CR4","doi-asserted-by":"publisher","unstructured":"Solomon A, Stephen R, Altomare D, Carrera E, Frisoni GB, Kulmala J, Molinuevo JL, Nilsson P, Ngandu T, Ribaldi F, Vellas B, Scheltens P, Kivipelto M. Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services \u2013 Part 4 of 6.\u00a0Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00875-8.","DOI":"10.1186\/s13195-021-00875-8"},{"key":"895_CR5","doi-asserted-by":"publisher","unstructured":"Brioschi Guevara A, Bieler M, Altomare D, Berthier M, Csajka C, Dautricourt S, D\u00e9monet JF, Dodich A, Frisoni GB, Miniussi C, Molinuevo JL, Ribaldi F, Scheltens P, Ch\u00e9telat G. Protocols for cognitive enhancement. A user manual for Brain Health Services \u2013 Part 5 of 6.\u00a0Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00844-1.","DOI":"10.1186\/s13195-021-00844-1"},{"key":"895_CR6","doi-asserted-by":"publisher","unstructured":"Milne R, Altomare D, Ribaldi F, Molinuevo JL, Frisoni GB, Brayne C. Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services \u2013 Part 6 of 6.\u00a0Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00885-6.","DOI":"10.1186\/s13195-021-00885-6"},{"issue":"10113","key":"895_CR7","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673\u2013734. https:\/\/doi.org\/10.1016\/S0140-6736(17)31363-6.","journal-title":"Lancet"},{"issue":"10248","key":"895_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6.","journal-title":"Lancet"},{"key":"895_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fnagi.2015.00134","volume":"7","author":"EM Arenaza-Urquijo","year":"2015","unstructured":"Arenaza-Urquijo EM, Wirth M, Ch\u00e9telat G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer\u2019s disease. Front Aging Neurosci. 2015;7:134. https:\/\/doi.org\/10.3389\/fnagi.2015.00134.","journal-title":"Front Aging Neurosci"},{"issue":"35","key":"895_CR10","doi-asserted-by":"publisher","first-page":"12638","DOI":"10.1523\/JNEUROSCI.2559-11.2011","volume":"31","author":"JE Peelle","year":"2011","unstructured":"Peelle JE, Troiani V, Grossman M, Wingfield A. Hearing loss in older adults affects neural systems supporting speech comprehension. J Neurosci. 2011;31(35):12638\u201343. https:\/\/doi.org\/10.1523\/JNEUROSCI.2559-11.2011.","journal-title":"J Neurosci"},{"issue":"2","key":"895_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/157340009788167347","volume":"5","author":"TF Hughes","year":"2009","unstructured":"Hughes TF, Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia. Curr Psychiatry Rev. 2009;5(2):73\u201392. https:\/\/doi.org\/10.2174\/157340009788167347.","journal-title":"Curr Psychiatry Rev"},{"key":"895_CR12","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","volume":"6","author":"BM Leon","year":"2015","unstructured":"Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6:1246\u201358.","journal-title":"World J Diabetes"},{"key":"895_CR13","doi-asserted-by":"publisher","first-page":"l1495","DOI":"10.1136\/bmj.l1495","volume":"365","author":"M Kivim\u00e4ki","year":"2019","unstructured":"Kivim\u00e4ki M, Singh-Manoux A, Pentti J, Sabia S, Nyberg ST, Alfredsson L, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019;365:l1495. https:\/\/doi.org\/10.1136\/bmj.l1495.","journal-title":"BMJ"},{"issue":"11","key":"895_CR14","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.biopsych.2017.09.025","volume":"82","author":"D Shalev","year":"2017","unstructured":"Shalev D, Arbuckle MR. Metabolism and memory: obesity, diabetes, and dementia. Biol Psychiatry. 2017;82(11):e81\u20133. https:\/\/doi.org\/10.1016\/j.biopsych.2017.09.025.","journal-title":"Biol Psychiatry"},{"issue":"s1","key":"895_CR15","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.3233\/JAD-180631","volume":"70","author":"R Peters","year":"2019","unstructured":"Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019;70(s1):S145\u2013s163. https:\/\/doi.org\/10.3233\/JAD-180631.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"895_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06028.x","volume":"1231","author":"JT Cacioppo","year":"2011","unstructured":"Cacioppo JT, Hawkley LC, Norman GJ, Berntson GG. Social isolation. Ann N Y Acad Sci. 2011;1231(1):17\u201322. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06028.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"895_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/abm\/kax033","volume":"52","author":"LC Kobayashi","year":"2018","unstructured":"Kobayashi LC, Steptoe A. Social isolation, loneliness, and health behaviors at older ages: longitudinal cohort study. Ann Behav Med. 2018;52(7):582\u201393. https:\/\/doi.org\/10.1093\/abm\/kax033.","journal-title":"Ann Behav Med"},{"key":"895_CR18","volume-title":"Risk reduction of cognitive decline and dementia","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Risk reduction of cognitive decline and dementia. Geneva: WHO guidelines; 2019."},{"issue":"3","key":"895_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/gps.4245","volume":"30","author":"K Deckers","year":"2015","unstructured":"Deckers K, van Boxtel MP, Schiepers OJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234\u201346. https:\/\/doi.org\/10.1002\/gps.4245.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"895_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12877-016-0342-y","volume":"16","author":"LOJ Killin","year":"2016","unstructured":"Killin LOJ, Starr JM, Shiue IJ, Russ TC. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 2016;16(1):175. https:\/\/doi.org\/10.1186\/s12877-016-0342-y.","journal-title":"BMC Geriatr"},{"issue":"3","key":"895_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330. https:\/\/doi.org\/10.1038\/s41588-019-0358-2.","journal-title":"Nat Genet"},{"key":"895_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","volume":"17","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee SJ, Wolters FJ, Ikram MK, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17:434\u201344.","journal-title":"Lancet Neurol"},{"issue":"1","key":"895_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther. 2011;3(1):1\u20131. https:\/\/doi.org\/10.1186\/alzrt59.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"895_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1474-4422(10)70159-9","volume":"9","author":"MN Rossor","year":"2010","unstructured":"Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9(8):793\u2013806. https:\/\/doi.org\/10.1016\/S1474-4422(10)70159-9.","journal-title":"Lancet Neurol"},{"issue":"3","key":"895_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253\u201360. https:\/\/doi.org\/10.1212\/WNL.0000000000000596.","journal-title":"Neurology"},{"issue":"1","key":"895_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"issue":"9","key":"895_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903\u20137. https:\/\/doi.org\/10.1038\/mp.2011.52.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"895_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1212\/WNL.46.3.673","volume":"46","author":"RH Myers","year":"1996","unstructured":"Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology. 1996;46(3):673\u20137. https:\/\/doi.org\/10.1212\/WNL.46.3.673.","journal-title":"Neurology"},{"issue":"7","key":"895_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.55.7.964","volume":"55","author":"AJ Slooter","year":"1998","unstructured":"Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55(7):964\u20138. https:\/\/doi.org\/10.1001\/archneur.55.7.964.","journal-title":"Arch Neurol"},{"issue":"9984","key":"895_CR30","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Lev\u00e4lahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5.","journal-title":"Lancet"},{"issue":"4","key":"895_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaneurol.2017.4365","volume":"75","author":"A Solomon","year":"2018","unstructured":"Solomon A, Turunen H, Ngandu T, Peltonen M, Lev\u00e4lahti E, Helisalmi S, et al. Effect of the Apolipoprotein E Genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75(4):462\u201370. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4365.","journal-title":"JAMA Neurol"},{"issue":"5","key":"895_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jama.2019.9879","volume":"322","author":"I Lourida","year":"2019","unstructured":"Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypp\u00f6nen E, Kuzma E, et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA. 2019;322(5):430\u20137. https:\/\/doi.org\/10.1001\/jama.2019.9879.","journal-title":"JAMA"},{"issue":"9","key":"895_CR33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41591-019-0547-7","volume":"25","author":"S Licher","year":"2019","unstructured":"Licher S, Ahmad S, Karamuji\u0107-\u010comi\u0107 H, Voortman T, Leening MJG, Ikram MA, et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nat Med. 2019;25(9):1364\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0547-7.","journal-title":"Nat Med"},{"issue":"4","key":"895_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/WAD.0b013e318211c83c","volume":"25","author":"ES Sharp","year":"2011","unstructured":"Sharp ES, Gatz M. Relationship between education and dementia: an updated systematic review. Alzheimer Dis Assoc Disord. 2011;25(4):289\u2013304. https:\/\/doi.org\/10.1097\/WAD.0b013e318211c83c.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"895_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/01.HTR.0000300227.67748.77","volume":"22","author":"JD Corrigan","year":"2007","unstructured":"Corrigan JD, Bogner J. Initial reliability and validity of the Ohio State University TBI Identification Method. J Head Trauma Rehabil. 2007;22(6):318\u201329. https:\/\/doi.org\/10.1097\/01.HTR.0000300227.67748.77.","journal-title":"J Head Trauma Rehabil"},{"issue":"33","key":"895_CR36","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"1","key":"895_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13011-018-0143-8","volume":"13","author":"H McKenna","year":"2018","unstructured":"McKenna H, Treanor C, O\u2019Reilly D, Donnelly M. Evaluation of the psychometric properties of self-reported measures of alcohol consumption: a COSMIN systematic review. Subst Abuse Treat Prev Policy. 2018;13(1):6. https:\/\/doi.org\/10.1186\/s13011-018-0143-8.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"895_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5530\/ijmedph.2016.2.4","volume":"6","author":"S Razi","year":"2016","unstructured":"Razi S, Manish G, Keshav G, Sukriti K, Gupta A. Site or size of waist circumference, which one is more important in metabolic syndrome? Int J Med Public Health. 2016;6:69\u201372.","journal-title":"Int J Med Public Health"},{"issue":"3","key":"895_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/geriatrics3030048","volume":"3","author":"M Lycke","year":"2018","unstructured":"Lycke M, Lefebvre T, Cool L, van Eygen K, Boterberg T, Schofield P, et al. Screening methods for age-related hearing loss in older patients with cancer: a review of the literature. Geriatrics (Basel). 2018;3(3):48. https:\/\/doi.org\/10.3390\/geriatrics3030048.","journal-title":"Geriatrics (Basel)"},{"issue":"2","key":"895_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"895_CR41","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1001\/jama.2020.6504","volume":"323","author":"B Levis","year":"2020","unstructured":"Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. JAMA. 2020;323:2290\u2013300.","journal-title":"JAMA"},{"issue":"3","key":"895_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/00003727-198811000-00008","volume":"11","author":"JE Lubben","year":"1988","unstructured":"Lubben JE. Assessing social networks among elderly populations. Fam Community Health. 1988;11(3):42\u201352. https:\/\/doi.org\/10.1097\/00003727-198811000-00008.","journal-title":"Fam Community Health"},{"issue":"1","key":"895_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0033-3182(93)71928-3","volume":"34","author":"HG Koenig","year":"1993","unstructured":"Koenig HG, Westlund RE, George LK, Hughes DC, Blazer DG, Hybels C. Abbreviating the Duke Social Support Index for use in chronically ill elderly individuals. Psychosomatics. 1993;34(1):61\u20139. https:\/\/doi.org\/10.1016\/S0033-3182(93)71928-3.","journal-title":"Psychosomatics"},{"issue":"2","key":"895_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jand.2013.09.018","volume":"114","author":"LG Sylvia","year":"2014","unstructured":"Sylvia LG, Bernstein EE, Hubbard JL, Keating L, Anderson EJ. Practical guide to measuring physical activity. J Acad Nutr Diet. 2014;114(2):199\u2013208. https:\/\/doi.org\/10.1016\/j.jand.2013.09.018.","journal-title":"J Acad Nutr Diet"},{"issue":"3","key":"895_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002258","volume":"14","author":"RS Desikan","year":"2017","unstructured":"Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med. 2017;14(3):e1002258. https:\/\/doi.org\/10.1371\/journal.pmed.1002258.","journal-title":"PLoS Med"},{"issue":"12","key":"895_CR46","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1093\/brain\/awv268","volume":"138","author":"V Escott-Price","year":"2015","unstructured":"Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer\u2019s disease. Brain. 2015;138(12):3673\u201384. https:\/\/doi.org\/10.1093\/brain\/awv268.","journal-title":"Brain"},{"issue":"2","key":"895_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/brain\/awy327","volume":"142","author":"CH Tan","year":"2019","unstructured":"Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, et al. Polygenic hazard score, amyloid deposition and Alzheimer\u2019s neurodegeneration. Brain. 2019;142(2):460\u201370. https:\/\/doi.org\/10.1093\/brain\/awy327.","journal-title":"Brain"},{"issue":"8","key":"895_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ejhg.2017.87","volume":"25","author":"H Holstege","year":"2017","unstructured":"Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JGJ, Weiss M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer\u2019s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017;25(8):973\u201381. https:\/\/doi.org\/10.1038\/ejhg.2017.87.","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"895_CR49","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(11):1505\u201321. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.220.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"895_CR50","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6(1):26801. https:\/\/doi.org\/10.1038\/srep26801.","journal-title":"Sci Rep"},{"key":"895_CR51","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019;76(9):1060\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632.","DOI":"10.1001\/jamaneurol.2019.1632"},{"issue":"3","key":"895_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1.","journal-title":"Nat Med"},{"key":"895_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"issue":"5","key":"895_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"8","key":"895_CR55","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"4","key":"895_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","volume":"19","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Riederer P, O\u2019Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19(4):244\u2013328. https:\/\/doi.org\/10.1080\/15622975.2017.1375556.","journal-title":"World J Biol Psychiatry"},{"key":"895_CR57","doi-asserted-by":"crossref","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","DOI":"10.1001\/jamaneurol.2016.6117"},{"issue":"21","key":"895_CR58","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89(21):2167\u201375. https:\/\/doi.org\/10.1212\/WNL.0000000000004667.","journal-title":"Neurology"},{"issue":"2","key":"895_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383. https:\/\/doi.org\/10.1038\/s41591-018-0304-3.","journal-title":"Nat Med"},{"issue":"1","key":"895_CR60","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1038\/s41467-020-19543-w","volume":"11","author":"JP Chhatwal","year":"2020","unstructured":"Chhatwal JP, Schultz AP, Dang Y, Ostaszewski B, Liu L, Yang HS, et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat Commun. 2020;11(1):6024. https:\/\/doi.org\/10.1038\/s41467-020-19543-w.","journal-title":"Nat Commun"},{"key":"895_CR61","doi-asserted-by":"publisher","unstructured":"Cullen NC, Leuzy A, Palmqvist S, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging. 2020;1:114\u201323. https:\/\/doi.org\/10.1038\/s43587-020-00003-5.","DOI":"10.1038\/s43587-020-00003-5"},{"key":"895_CR62","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"895_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","volume":"14","author":"JD Rohrer","year":"2015","unstructured":"Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative ( GENFI ) study: a cross-sectional analysis. Lancet Neurol. 2015;14:253\u201362.","journal-title":"Lancet Neurol"},{"issue":"2","key":"895_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.10424","volume":"53","author":"JM Schott","year":"2003","unstructured":"Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, et al. Assessing the onset of structural change in familial Alzheimer\u2019s disease. Ann Neurol. 2003;53(2):181\u20138. https:\/\/doi.org\/10.1002\/ana.10424.","journal-title":"Ann Neurol"},{"issue":"9020","key":"895_CR65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0140-6736(96)05228-2","volume":"348","author":"NC Fox","year":"1996","unstructured":"Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer\u2019s disease. Lancet. 1996;348(9020):94\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(96)05228-2.","journal-title":"Lancet"},{"issue":"2","key":"895_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67\u201377. https:\/\/doi.org\/10.1038\/nrneurol.2009.215.","journal-title":"Nat Rev Neurol"},{"key":"895_CR67","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jalz.2013.07.003","volume":"10","author":"DLG Hill","year":"2014","unstructured":"Hill DLG, Schwarz AJ, Isaac M, et al. Coalition Against Major Diseases\/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:421\u2013429.e423.","journal-title":"Alzheimers Dement"},{"key":"895_CR68","doi-asserted-by":"publisher","unstructured":"Lombardi G, Crescioli G, Cavedo E, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer\u2019s disease in people with mild cognitive impairment. Cochrane Database Syst Rev. 2020;3(3):CD009628. https:\/\/doi.org\/10.1002\/14651858.CD009628.pub2.","DOI":"10.1002\/14651858.CD009628.pub2"},{"issue":"11","key":"895_CR69","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1007\/s00415-020-10040-0","volume":"267","author":"T Rittman","year":"2020","unstructured":"Rittman T. Neurological update: neuroimaging in dementia. J Neurol. 2020;267(11):3429\u201335. https:\/\/doi.org\/10.1007\/s00415-020-10040-0.","journal-title":"J Neurol"},{"issue":"1","key":"895_CR70","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1038\/s41467-020-18201-5","volume":"11","author":"M Veldsman","year":"2020","unstructured":"Veldsman M, Tai X-Y, Nichols T, Smith S, Peixoto J, Manohar S, et al. Cerebrovascular risk factors impact frontoparietal network integrity and executive function in healthy ageing. Nat Commun. 2020;11(1):4340. https:\/\/doi.org\/10.1038\/s41467-020-18201-5.","journal-title":"Nat Commun"},{"issue":"8","key":"895_CR71","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(13)70124-8.","journal-title":"Lancet Neurol"},{"issue":"jul26 1","key":"895_CR72","doi-asserted-by":"publisher","first-page":"c3666","DOI":"10.1136\/bmj.c3666","volume":"341","author":"S Debette","year":"2010","unstructured":"Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341(jul26 1):c3666. https:\/\/doi.org\/10.1136\/bmj.c3666.","journal-title":"BMJ"},{"issue":"jul06 1","key":"895_CR73","doi-asserted-by":"publisher","first-page":"b2477","DOI":"10.1136\/bmj.b2477","volume":"339","author":"D Inzitari","year":"2009","unstructured":"Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. Bmj. 2009;339(jul06 1):b2477. https:\/\/doi.org\/10.1136\/bmj.b2477.","journal-title":"Bmj"},{"issue":"11","key":"895_CR74","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jalz.2018.06.3061","volume":"14","author":"E Ku\u017ama","year":"2018","unstructured":"Ku\u017ama E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement. 2018;14(11):1416\u201326. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.3061.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"895_CR75","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jalz.2018.04.007","volume":"14","author":"D Bos","year":"2018","unstructured":"Bos D, Wolters FJ, Darweesh SKL, Vernooij MW, de Wolf F, Ikram MA, et al. Cerebral small vessel disease and the risk of dementia: a systematic review and meta-analysis of population-based evidence. Alzheimers Dement. 2018;14(11):1482\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2018.04.007.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"895_CR76","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967\u201372. https:\/\/doi.org\/10.1136\/jnnp.55.10.967.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"895_CR77","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"EL Koedam","year":"2011","unstructured":"Koedam EL, Lehmann M, van der Flier WM, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011;21(12):2618\u201325. https:\/\/doi.org\/10.1007\/s00330-011-2205-4.","journal-title":"Eur Radiol"},{"issue":"5","key":"895_CR78","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268\u201372. https:\/\/doi.org\/10.1159\/000117270.","journal-title":"Eur Neurol"},{"issue":"6","key":"895_CR79","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sj\u00f6gren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318\u201322. https:\/\/doi.org\/10.1161\/01.STR.32.6.1318.","journal-title":"Stroke"},{"issue":"6","key":"895_CR80","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00234-019-02188-y","volume":"61","author":"MW Vernooij","year":"2019","unstructured":"Vernooij MW, Pizzini FB, Schmidt R, Smits M, Yousry TA, Bargallo N, et al. Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. Neuroradiology. 2019;61(6):633\u201342. https:\/\/doi.org\/10.1007\/s00234-019-02188-y.","journal-title":"Neuroradiology"},{"issue":"2","key":"895_CR81","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u20136. https:\/\/doi.org\/10.2214\/ajr.149.2.351.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"895_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","volume":"19","author":"BC Dickerson","year":"2009","unstructured":"Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497\u2013510. https:\/\/doi.org\/10.1093\/cercor\/bhn113.","journal-title":"Cereb Cortex"},{"key":"895_CR83","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.nicl.2020.102199","volume":"26","author":"J Giorgio","year":"2020","unstructured":"Giorgio J, Landau SM, Jagust WJ, Tino P, Kourtzi Z. Alzheimer\u2019s Disease Neuroimaging I. Modelling prognostic trajectories of cognitive decline due to Alzheimer\u2019s disease. Neuroimage Clin. 2020;26:102199. https:\/\/doi.org\/10.1016\/j.nicl.2020.102199.","journal-title":"Neuroimage Clin"},{"key":"895_CR84","doi-asserted-by":"publisher","first-page":"101954","DOI":"10.1016\/j.nicl.2019.101954","volume":"24","author":"D Archetti","year":"2019","unstructured":"Archetti D, Ingala S, Venkatraghavan V, Wottschel V, Young AL, Bellio M, et al. Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer\u2019s disease. NeuroImage Clin. 2019;24:101954. https:\/\/doi.org\/10.1016\/j.nicl.2019.101954.","journal-title":"NeuroImage Clin"},{"issue":"1","key":"895_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-49656-2","volume":"9","author":"CK Fisher","year":"2019","unstructured":"Fisher CK, Smith AM, Walsh JR. Machine learning for comprehensive forecasting of Alzheimer\u2019s disease progression. Sci Rep. 2019;9(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-019-49656-2.","journal-title":"Sci Rep"},{"issue":"12","key":"895_CR86","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000005161","volume":"90","author":"A Pilotto","year":"2018","unstructured":"Pilotto A, Premi E, Paola Caminiti S, Presotto L, Turrone R, Alberici A, et al. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology. 2018;90(12):e1029\u201337. https:\/\/doi.org\/10.1212\/WNL.0000000000005161.","journal-title":"Neurology"},{"key":"895_CR87","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275\u201383.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"895_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58. https:\/\/doi.org\/10.1186\/s40478-016-0315-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"895_CR89","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2967\/jnumed.109.062265","volume":"50","author":"CJ Endres","year":"2009","unstructured":"Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nuclear Med. 2009;50(8):1276\u201382. https:\/\/doi.org\/10.2967\/jnumed.109.062265.","journal-title":"J Nuclear Med"},{"issue":"5","key":"895_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.115.168179","volume":"57","author":"NB Nabulsi","year":"2016","unstructured":"Nabulsi NB, Mercier J, Holden D, Carr\u00e9 S, Najafzadeh S, Vandergeten MC, et al. Synthesis and preclinical evaluation of 11C-UCB-J as a PET Tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nuclear Med. 2016;57(5):777\u201384. https:\/\/doi.org\/10.2967\/jnumed.115.168179.","journal-title":"J Nuclear Med"},{"issue":"4","key":"895_CR91","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2018-318212","volume":"90","author":"XH Hou","year":"2019","unstructured":"Hou XH, Feng L, Zhang C, Cao XP, Tan L, Yu JT. Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. 2019;90(4):373\u20139. https:\/\/doi.org\/10.1136\/jnnp-2018-318212.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"895_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136181","volume":"10","author":"EY Tang","year":"2015","unstructured":"Tang EY, Harrison SL, Errington L, et al. Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One. 2015;10:e0136181.","journal-title":"PLoS One"},{"issue":"9","key":"895_CR93","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","volume":"5","author":"M Kivipelto","year":"2006","unstructured":"Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5(9):735\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(06)70537-3.","journal-title":"Lancet Neurol"},{"issue":"4","key":"895_CR94","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11121-012-0313-2","volume":"14","author":"KJ Anstey","year":"2013","unstructured":"Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer\u2019s disease for use in population health approaches to prevention. Prev Sci. 2013;14(4):411\u201321. https:\/\/doi.org\/10.1007\/s11121-012-0313-2.","journal-title":"Prev Sci"},{"issue":"1","key":"895_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086141","volume":"9","author":"KJ Anstey","year":"2014","unstructured":"Anstey KJ, Cherbuin N, Herath PM, Qiu C, Kuller LH, Lopez OL, et al. A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI. PLoS One. 2014;9(1):e86141. https:\/\/doi.org\/10.1371\/journal.pone.0086141.","journal-title":"PLoS One"},{"key":"895_CR96","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jalz.2013.11.006","volume":"10","author":"DE Barnes","year":"2014","unstructured":"Barnes DE, Beiser AS, Lee A, et al. Development and validation of a brief dementia screening indicator for primary care. Alzheimers Dement. 2014;10:656\u2013665.e651.","journal-title":"Alzheimers Dement"},{"key":"895_CR97","doi-asserted-by":"publisher","unstructured":"Exalto LG, Biessels GJ, Karter AJ, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013;1(3):183\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(13)70048-2.","DOI":"10.1016\/S2213-8587(13)70048-2"},{"issue":"7","key":"895_CR98","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/STROKEAHA.120.027473","volume":"51","author":"EYH Tang","year":"2020","unstructured":"Tang EYH, Price CI, Robinson L, Exley C, Desmond DW, K\u00f6hler S, et al. Assessing the predictive validity of simple dementia risk models in harmonised stroke cohorts. Stroke. 2020;51(7):2095\u2013102. https:\/\/doi.org\/10.1161\/STROKEAHA.120.027473.","journal-title":"Stroke"},{"issue":"4","key":"895_CR99","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1016\/S2214-109X(20)30062-0","volume":"8","author":"BCM Stephan","year":"2020","unstructured":"Stephan BCM, Pakpahan E, Siervo M, Licher S, Muniz-Terrera G, Mohan D, et al. Prediction of dementia risk in low-income and middle-income countries (the 10\/66 Study): an independent external validation of existing models. Lancet Glob Health. 2020;8(4):e524\u201335. https:\/\/doi.org\/10.1016\/S2214-109X(20)30062-0.","journal-title":"Lancet Glob Health"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00895-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:16:30Z","timestamp":1636121790000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00895-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The paper was amended to add a DOI in references part of the Brain Health Services series.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GBF reports grants from Alzheimer Forum Suisse, Acad\u00e9mie Suisse des Sciences M\u00e9dicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l\u2019Alzheimer, IXICO, Merz Pharma, Nestl\u00e9, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer\u2019s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.JLM is currently a full time employee of Lundbeck and has previously served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}